

M1RP: 353 samples (FFPE and cfDNA)

Somatic mutation & heterozygous SNP-based tumor content estimated for all samples.
Mutations must be on unamplified genes.

Group 1

n = 195

Mutation-based estimation is used.

Somatic mutation used is in $\geq 75\%$ of same-patient samples.

Mutation must be independently called.

Group 2

n = 75

SNP estimation is used.

Somatic mutation used is in $< 75\%$ of same-patient samples.

Group 3

n = 41

Mutation-based estimation is used.

SNP-based estimation is not feasible due to low TC or no regions of copy loss LOH.

Mutation used is in $< 75\%$ of same-patient samples or dependently called.

42 samples had no detectable tumor with any method